Edward A. O’Neill

6.4k citations

91 papers · 4.7k indexed · 2 hit papers · h-index 30

Molecular Biology top 2%
Oncology top 5%
Endocrinology, Diabetes and Metabolism top 2%
Immunology top 5%
Genetics top 5%

Co-authors: Thomas J. Kelly Stephen J. O’Keefe Michael J. Tocci Randall L. Kincaid Nicolas Mermod Robert Tjian Jun‐ichi Tamura Betsy Frantz
Topics: Diabetes Treatment and Management (34 papers)Diabetes Management and Research (21 papers)Melanoma and MAPK Pathways (18 papers)
Cited by: Endocrinology, Diabetes and Metabolism Molecular Biology Immunology
Journals: Nature Science Cell
Partner nations: United States Japan China

In The Last Decade

Edward A. O’Neill

90 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin

1992 760 citations Stephen J. O’Keefe, Jun‐ichi Tamura et al. Nature profile →
The proline-rich transcriptional activator of CTF/NF-I is distinct from the replication and DNA binding domain

1989 725 citations Nicolas Mermod, Edward A. O’Neill et al. Cell profile →

Peers

Countries citing papers authored by Edward A. O’Neill

Since Specialization

Citations

This map shows the geographic impact of Edward A. O’Neill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward A. O’Neill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward A. O’Neill more than expected).

Fields of papers citing papers by Edward A. O’Neill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward A. O’Neill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward A. O’Neill. The network helps show where Edward A. O’Neill may publish in the future.

Co-authorship network of co-authors of Edward A. O’Neill

This figure shows the co-authorship network connecting the top 25 collaborators of Edward A. O’Neill. A scholar is included among the top collaborators of Edward A. O’Neill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward A. O’Neill. Edward A. O’Neill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults 2024 ·The Journal of Clinical Pharmacology ·Jesse C. Nussbaum,Azher Hussain,P. Butera,Anthony Ford,Michael M. Kitt,Edward A. O’Neill,Steven A. Smith,Gabriel Vargas,Terry O’Reilly,Chris Wynne,S. Aubrey Stoch,Marian Iwamoto	4
2	A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin 2021 ·Diabetes Obesity and Metabolism ·Yutaka Seino,Kohei Kaku,Takashi Kadowaki,Taro Okamoto,Asako Sato,(unknown),Edward A. O’Neill,Samuel S. Engel,Keith D. Kaufman	3
3	A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control 2021 ·Diabetes Obesity and Metabolism ·Takashi Kadowaki,Yutaka Seino,Kohei Kaku,Taro Okamoto,(unknown),Asako Sato,(unknown),Nobuyuki Oshima,Ira Gantz,Edward A. O’Neill,Samuel S. Engel,(unknown)	4
4	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin 2021 ·Diabetes Obesity and Metabolism ·Kohei Kaku,Takashi Kadowaki,Yutaka Seino,Taro Okamoto,(unknown),Asako Sato,Edward A. O’Neill,Samuel S. Engel,Keith D. Kaufman	4
5	A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control 2017 ·Diabetes Therapy ·(unknown),Ira Gantz,Taro Okamoto,Yuka Ito,Asako Sato,Kotoba Okuyama,Edward A. O’Neill,Samuel S. Engel,Eseng Lai	5
6	Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials 2015 ·Diabetes Therapy ·(unknown),Lei Xu,Edward A. O’Neill,Barry J. Goldstein,Keith D. Kaufman,Samuel S. Engel	8
7	Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia 2013 ·The Aging Male ·Steven A. Kaplan,Jeannette Y. Lee,Edward A. O’Neill,Alan G. Meehan,John W. Kusek	40
8	Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus 2012 ·Metabolic Syndrome and Related Disorders ·Harold Bays,Hilde Giezek,James M. McKenney,Edward A. O’Neill,Andrew M. Tershakovec	10
9	Risk of acute renal failure in patients with Type 2 diabetes mellitus 2011 ·Diabetic Medicine ·Cynthia J. Girman,Tzuyung D. Kou,Kimberly G. Brodovicz,Charles M. Alexander,Edward A. O’Neill,Samuel S. Engel,Debora Williams‐Herman,Leonid Katz	67
10	Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial 2010 ·Diabetes Obesity and Metabolism ·(unknown),Thomas Seck,Yong Chen,Karl J. Krobot,Edward A. O’Neill,(unknown),Keith D. Kaufman,Debora Williams‐Herman,B. J. Goldstein	136
11	Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate 2010 ·Xenobiotica ·Xiang‐Qing Yu,Jeff Kramer,(unknown),Edward A. O’Neill,(unknown),Tamás Oravecz,Alan Wilson	15
12	Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes 2010 ·Diabetes Obesity and Metabolism ·Cynthia J. Girman,Tzuyung D. Kou,(unknown),Charles M. Alexander,Edward A. O’Neill,Debora Williams‐Herman,Leonid Katz	161
13	p38 MAP kinase inhibitors. Part 5: Discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold 2006 ·Bioorganic & Medicinal Chemistry Letters ·S. Natarajan,Luping Liu,(unknown),James E. Thompson,Edward A. O’Neill,Stephen J. O’Keefe,Kalpit A. Vora,Raymond J. Cvetovich,John Y. L. Chung,Ester Carballo‐Jane,Denise M. Visco	11
14	Lattice stabilization and enhanced diffraction in human p38α crystals by protein engineering 2003 ·Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics ·Sangita B. Patel,Patricia M. Cameron,(unknown),Edward A. O’Neill,Joseph W. Becker,Giovanna Scapin	37
15	T cell responses in calcineurin A alpha-deficient mice. 1996 ·The Journal of Experimental Medicine ·(unknown),(unknown),Jue Chen,Daniel Ladd,Erguang Li,Frederick W. Alt,Greg Wiederrecht,John G. Cryan,Edward A. O’Neill,Christine E. Seidman,Abul K. Abbas,J G Seidman	129
16	A Novel FK506 Binding Protein Can Mediate the Immunosuppressive Effects of FK506 and Is Associated with the Cardiac Ryanodine Receptor 1995 ·Journal of Biological Chemistry ·(unknown),Mary M. Martin,A.P. Timerman,Candace J. Sabers,Sidney Fleischer,Thomas J. Lukas,Robert T. Abraham,Stephen J. O’Keefe,Edward A. O’Neill,Gregory J. Wiederrecht	145
17	FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurinbreakdown → 1992 ·Nature ·Stephen J. O’Keefe,Jun‐ichi Tamura,Randall L. Kincaid,Michael J. Tocci,Edward A. O’Neill	760
18	The proline-rich transcriptional activator of CTF/NF-I is distinct from the replication and DNA binding domainbreakdown → 1989 ·Cell ·Nicolas Mermod,Edward A. O’Neill,Thomas J. Kelly,Robert Tjian	725
19	Replication of adenovirus and SV40 chromosomes in vitro 1987 ·Philosophical transactions of the Royal Society of London. Series B, Biological sciences ·Thomas J. Kelly,Philip J. Rosenfeld,Ronald J. Wides,Edward A. O’Neill,(unknown),Marc S. Wold	3
20	Sequence-Specific Interactions Between Cellular DNA-Binding Proteins and the Adenovirus origin of DNA Replication 1987 ·Molecular and Cellular Biology ·Philip J. Rosenfeld,Edward A. O’Neill,Ronald J. Wides,Thomas J. Kelly	73

About Edward A. O’Neill

Edward A. O’Neill is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Medicine and Molecular Biology, having authored 91 papers that have together received 4.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (34 papers), Diabetes Management and Research (21 papers) and Melanoma and MAPK Pathways (18 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (765 citations), Molecular Biology (2.9k citations) and Immunology (735 citations). Edward A. O’Neill has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Thomas J. Kelly, Stephen J. O’Keefe, Michael J. Tocci, Randall L. Kincaid, Nicolas Mermod, Robert Tjian, Jun‐ichi Tamura, Betsy Frantz, Keith D. Kaufman and Philip J. Rosenfeld. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact